.png){kind=icon}
.png){kind=icon}
Return
Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study
.png){kind=icon}
OA
AI
T
S
K
E
Y
Y
S
K
H
S
T
T
DOI：10.1016/j.vaccine.2026.128871.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Phase 3 trial of recombinant protein vaccine S-268024 booster dose vs NVX-CoV2373. • S-268024 noninferior to NVX-CoV2373 for immunogenicity against COVID-19. • S-268024 superior in geometric mean titer of neutralizing antibodies vs NVX-CoV2373. • Broad neutralization against multiple JN.1-related subvariants by S-268024 booster. • Acceptable safety profile of S-268024 booster with minimal daily activity impact.
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.5
Papers:
2.1K
Citations:
4.7W
Organization
Cited Papers